Adma Biologics (ADMA) Other Non Operating Income (2013 - 2026)
Adma Biologics' (ADMA) quarterly Other Non Operating Income came in at $2.1 million in Q4 2025, up 2516.28% YoY from $79425.8 in Q4 2024, and up 9995.24% on a QoQ basis from -$21000.0 in Q3 2025.
Adma Biologics (ADMA) Other Non Operating Income (2013 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 9 years of Other Non Operating Income data on file, last reported at $2.1 million in Q4 2025.
- Quarterly Other Non Operating Income rose 2516.28% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $834000.0 (up 532.12% YoY) and the FY2025 annual result came in at $1.9 million, up 1075.65% from the prior year.
- Other Non Operating Income improved to $2.1 million in Q4 2025, from -$21000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q4 2025 to a low of -$1.2 million in Q2 2025.
- A 5-year average of -$28525.2 and a median of -$45500.0 in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 2516.28% in 2025, down 7143.75% in 2025.
- Tracing ADMA's Other Non Operating Income over 5 years: stood at -$252000.0 in 2021, then sank by 74.23% to -$439058.0 in 2022, then jumped by 77.0% to -$101000.0 in 2023, then gained by 14.85% to -$86000.0 in 2024, then surged by 2516.28% to $2.1 million in 2025.
- The last three Other Non Operating Income figures came in at $2.1 million (Q4 2025), -$21000.0 (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22,000.00 |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | -64,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Sep 30, 2024 | -56,000.00 |
| Jun 30, 2024 | -16,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Dec 31, 2023 | -101,000.00 |
| Sep 30, 2023 | -145,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Dec 31, 2022 | -439,058.00 |
| Sep 30, 2022 | -9,641.00 |
| Jun 30, 2022 | -19,421.00 |
| Mar 31, 2022 | -166,880.00 |
| Dec 31, 2021 | -252,000.00 |
| Sep 30, 2021 | 18,546.00 |
| Dec 31, 2020 | 1.03 Mn |